Category: testosterone

AndroFeme 1 licensed for hypoactive sexual desire dysfunction in postmenopausal women

Lawley Pharmaceuticals  has obtained approval for registration of AndroFeme® 1 in the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →

Read more

Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1

Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →

Read more

Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1

Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →

Read more

TGA accepts AndroFeme 1 for evaluation in postmenopausal women with Hypoactive Sexual Desire Dysfunction.

TGA accepts AndroFeme 1 for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019  — Lawley Pharmaceuticals today announced AndroFeme 1,… Continue Reading →

Read more

Global Consensus Position Statement on the Use of Testosterone Therapy for Women

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women was simultaneously published on the 2nd September 2019 in Maturitas, Journal… Continue Reading →

Read more

Gender disparity in sexual health options for women: Experts call on pharma and drug regulators to address

  In 2015 Comment in the prestigious medical journal Lancet Diabetes & Endocrinology by two of the world’s leading female sexual health specialists, Prof…. Continue Reading →

Read more

BBC Menopause and testosterone replacement therapy

Over 900 specialist menopause physicians from around the world attended The European Menopause and Andropause Society conference held in Berlin on 15-17th May 2019. Numerous… Continue Reading →

Read more

Effects of testosterone therapy in women – new systematic review and meta-analysis

It has been over a decade since the last systematic review and meta-analysis on the effects of testosterone for women was conducted as an… Continue Reading →

Read more

Hypoactive Sexual Desire Disorder (HSDD) re-defined

In late 2018 the World Health Organisation (WHO) released an update to The International Classification of Disease (ICD). ICD is a system of medical coding created… Continue Reading →

Read more

Axiron® discontinued – Upgrade to AndroForte® 5

Axiron® discontinued – Upgrade to AndroForte® 5   Axiron 2% testosterone solution has been discontinued in Australia effective 4th December 2017 after Lilly terminated its… Continue Reading →

Read more